Hancock Whitney Corp Takes Position in Organon & Co. (NYSE:OGN)

Hancock Whitney Corp acquired a new position in Organon & Co. (NYSE:OGN) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 42,545 shares of the company’s stock, valued at approximately $881,000.

Several other large investors also recently added to or reduced their stakes in OGN. Norges Bank bought a new stake in Organon & Co. during the fourth quarter worth about $26,321,000. Coldstream Capital Management Inc. purchased a new stake in Organon & Co. in the fourth quarter worth approximately $237,000. Quest Partners LLC bought a new position in Organon & Co. during the fourth quarter valued at approximately $168,000. Franklin Resources Inc. grew its position in Organon & Co. by 55.7% during the fourth quarter. Franklin Resources Inc. now owns 180,815 shares of the company’s stock valued at $2,607,000 after acquiring an additional 64,683 shares during the last quarter. Finally, EverSource Wealth Advisors LLC raised its stake in shares of Organon & Co. by 92.4% during the fourth quarter. EverSource Wealth Advisors LLC now owns 4,321 shares of the company’s stock worth $62,000 after acquiring an additional 2,075 shares in the last quarter. Institutional investors own 77.43% of the company’s stock.

Analysts Set New Price Targets

Separately, JPMorgan Chase & Co. cut shares of Organon & Co. from a “neutral” rating to an “underweight” rating and lifted their target price for the stock from $18.00 to $20.00 in a research report on Friday, September 6th.

Organon & Co. Trading Down 3.4 %

Shares of NYSE OGN opened at $19.49 on Monday. The stock has a market cap of $5.01 billion, a P/E ratio of 4.77, a price-to-earnings-growth ratio of 0.89 and a beta of 0.85. The company has a debt-to-equity ratio of 60.05, a current ratio of 1.64 and a quick ratio of 1.17. Organon & Co. has a 1 year low of $10.84 and a 1 year high of $23.10. The firm has a 50-day moving average of $21.00 and a 200 day moving average of $20.11.

Organon & Co. (NYSE:OGN) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $1.12 earnings per share for the quarter, beating the consensus estimate of $1.08 by $0.04. The firm had revenue of $1.61 billion during the quarter, compared to the consensus estimate of $1.61 billion. Organon & Co. had a negative return on equity of 840.29% and a net margin of 15.76%. The company’s revenue was down .1% on a year-over-year basis. During the same period last year, the company earned $1.31 earnings per share. As a group, sell-side analysts expect that Organon & Co. will post 4.14 EPS for the current fiscal year.

Organon & Co. Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, September 12th. Stockholders of record on Friday, August 16th were issued a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a dividend yield of 5.75%. The ex-dividend date was Friday, August 16th. Organon & Co.’s payout ratio is 27.38%.

Organon & Co. Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.